Russell T Burke Selected Research

6- (1H- indazol- 6- yl)- N- (4- morpholinophenyl)imidazo(1,2- a)pyrazin- 8- amine

2/2014

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Russell T Burke Research Topics

Disease

5	Neoplasms (Cancer) 01/2018 - 02/2014
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/2014

Drug/Important Bio-Agent (IBA)

2	selinexorIBA 06/2017 - 09/2015
2	Pharmaceutical PreparationsIBA 06/2017 - 01/2016
1	Tumor Suppressor Protein p53IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 06/2017
1	Protein Isoforms (Isoforms)IBA 02/2014
1	fostamatinibIBA 02/2014
1	idelalisibIBA 02/2014
1	Syk KinaseIBA 02/2014
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 02/2014
1	6- (1H- indazol- 6- yl)- N- (4- morpholinophenyl)imidazo(1,2- a)pyrazin- 8- amineIBA 02/2014

Therapy/Procedure

3	Therapeutics 01/2018 - 09/2015